Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Computed Tomography | Research

Preserved ratio impaired spirometry is associated with small airway dysfunction and reduced total lung capacity

Authors: Ningning Zhao, Fan Wu, Jieqi Peng, Youlan Zheng, Heshen Tian, Huajing Yang, Zhishan Deng, Zihui Wang, Haiqing Li, Xiang Wen, Shan Xiao, Peiyu Huang, Cuiqiong Dai, Lifei Lu, Kunning Zhou, Shengtang Chen, Yumin Zhou, Pixin Ran

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background:

Preserved ratio impaired spirometry (PRISm) refers to decreased forced expiratory volume in 1 s (FEV1) in the setting of preserved ratio. Little is known about the role of PRISm and its complex relation with small airway dysfunction (SAD) and lung volume. Therefore, we aimed to investigate the associations between PRISm and SAD and lung volume.

Methods:

We conducted a cross-sectional community-dwelling study in China. Demographic data, standard respiratory epidemiology questionnaire, spirometry, impulse oscillometry (IOS) and computed tomography (CT) data were collected. PRISm was defined as post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 < 80% predicted. Spirometry-defined SAD was defined as at least two of three of the post-bronchodilator maximal mid-expiratory flow (MMEF), forced expiratory flow 50% (FEF50), and forced expiratory flow 75% (FEF75) less than 65% of predicted. IOS-defined SAD and CT-defined gas trapping were defined by the fact that the cutoff value of peripheral airway resistance R5–R20 > 0.07 kPa/L/s and LAA− 856>20%, respectively. Analysis of covariance and logistic regression were used to determine associations between PRISm and SAD and lung volume. We then repeated the analysis with a lower limit of normal definition of spirometry criteria and FVC definition of PRISm. Moreover, we also performed subgroup analyses in ever smoker, never smoker, subjects without airway reversibility or self-reported diagnosed asthma, and subjects with CT-measured total lung capacity ≥70% of predicted.

Results:

The final analysis included 1439 subjects. PRISm had higher odds and more severity in spirometry-defined SAD (pre-bronchodilator: odds ratio [OR]: 5.99, 95% confidence interval [95%CI]: 3.87–9.27, P < 0.001; post-bronchodilator: OR: 14.05, 95%CI: 8.88–22.24, P < 0.001), IOS-defined SAD (OR: 2.89, 95%CI: 1.82–4.58, P < 0.001), and CT-air trapping (OR: 2.01, 95%CI: 1.08–3.72, P = 0.027) compared with healthy control after adjustment for confounding factors. CT-measured total lung capacity in PRISm was lower than that in healthy controls (4.15 ± 0.98 vs. 4.78 ± 1.05 L, P < 0.05), after adjustment. These results were robust in repeating analyses and subgroup analyses.

Conclusion:

Our finding revealed that PRISm was associated with SAD and reduced total lung capacity. Future studies to identify the underlying mechanisms and longitudinal progression of PRISm are warranted.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wan ES, Hokanson JE, Murphy JR, et al. Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med. 2011;184(1):57–63.PubMedPubMedCentralCrossRef Wan ES, Hokanson JE, Murphy JR, et al. Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med. 2011;184(1):57–63.PubMedPubMedCentralCrossRef
2.
go back to reference Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.PubMedPubMedCentralCrossRef Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.PubMedPubMedCentralCrossRef
3.
go back to reference Guerra S, Sherrill DL, Venker C, et al. Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax. 2010;65(6):499–504.PubMedCrossRef Guerra S, Sherrill DL, Venker C, et al. Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax. 2010;65(6):499–504.PubMedCrossRef
4.
go back to reference Iyer VN, Schroeder DR, Parker KO, et al. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest. 2011;139(4):878–86.PubMedCrossRef Iyer VN, Schroeder DR, Parker KO, et al. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest. 2011;139(4):878–86.PubMedCrossRef
5.
go back to reference Mannino DM, McBurnie MA, Tan W, et al. Restricted spirometry in the Burden of Lung Disease Study. Int J Tuberc Lung Dis. 2012;16(10):1405–11.PubMed Mannino DM, McBurnie MA, Tan W, et al. Restricted spirometry in the Burden of Lung Disease Study. Int J Tuberc Lung Dis. 2012;16(10):1405–11.PubMed
7.
go back to reference Siddharthan T, Grigsby M, Miele CH, et al. Prevalence and risk factors of restrictive spirometry in a cohort of Peruvian adults. Int J Tuberc Lung Dis. 2017;21(9):1062–8.PubMedCrossRef Siddharthan T, Grigsby M, Miele CH, et al. Prevalence and risk factors of restrictive spirometry in a cohort of Peruvian adults. Int J Tuberc Lung Dis. 2017;21(9):1062–8.PubMedCrossRef
8.
go back to reference Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020;55(1):1901217.PubMedCrossRef Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020;55(1):1901217.PubMedCrossRef
9.
go back to reference Backman H, Eriksson B, Hedman L, et al. Restrictive spirometric pattern in the general adult population: Methods of defining the condition and consequences on prevalence. Respir Med. 2016;120:116–23.PubMedCrossRef Backman H, Eriksson B, Hedman L, et al. Restrictive spirometric pattern in the general adult population: Methods of defining the condition and consequences on prevalence. Respir Med. 2016;120:116–23.PubMedCrossRef
10.
go back to reference Wan ES, Fortis S, Regan EA, et al. Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. Am J Respir Crit Care Med. 2018;198(11):1397–405.PubMedPubMedCentralCrossRef Wan ES, Fortis S, Regan EA, et al. Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. Am J Respir Crit Care Med. 2018;198(11):1397–405.PubMedPubMedCentralCrossRef
11.
go back to reference Higbee DH, Granell R, Davey Smith G, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022;10(2):149–57.PubMedCrossRef Higbee DH, Granell R, Davey Smith G, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022;10(2):149–57.PubMedCrossRef
12.
go back to reference Wan ES, Balte P, Schwartz JE, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults. JAMA. 2021;326(22):2287–98.PubMedPubMedCentralCrossRef Wan ES, Balte P, Schwartz JE, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults. JAMA. 2021;326(22):2287–98.PubMedPubMedCentralCrossRef
14.
go back to reference Usmani OS, Dhand R, Lavorini F, Price D. Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease. Mayo Clin Proc. 2021;96(9):2448–2463. Usmani OS, Dhand R, Lavorini F, Price D. Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease. Mayo Clin Proc. 2021;96(9):2448–2463.
15.
go back to reference Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.PubMedCrossRef Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.PubMedCrossRef
16.
go back to reference Stockley JA, Ismail AM, Hughes SM, et al. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency. Eur Respir J. 2017;49(3):1602055.PubMedCrossRef Stockley JA, Ismail AM, Hughes SM, et al. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency. Eur Respir J. 2017;49(3):1602055.PubMedCrossRef
17.
go back to reference Young KA, Strand M, Ragland MF, et al. Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study. Chronic Obstr Pulm Dis. 2019;6(5):414–29.PubMedPubMedCentral Young KA, Strand M, Ragland MF, et al. Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study. Chronic Obstr Pulm Dis. 2019;6(5):414–29.PubMedPubMedCentral
18.
go back to reference Barnes PJ, Vestbo J, Calverley PM. The Pressing Need to Redefine “COPD”. Chronic Obstr Pulm Dis. 2019;6(5):380–3.PubMedPubMedCentral Barnes PJ, Vestbo J, Calverley PM. The Pressing Need to Redefine “COPD”. Chronic Obstr Pulm Dis. 2019;6(5):380–3.PubMedPubMedCentral
19.
go back to reference Wu F, Zhou Y, Peng J, et al. Rationale and design of the Early Chronic Obstructive Pulmonary Disease (ECOPD) study in Guangdong, China: a prospective observational cohort study. J Thorac Dis. 2021;13(12):6924–35.PubMedPubMedCentralCrossRef Wu F, Zhou Y, Peng J, et al. Rationale and design of the Early Chronic Obstructive Pulmonary Disease (ECOPD) study in Guangdong, China: a prospective observational cohort study. J Thorac Dis. 2021;13(12):6924–35.PubMedPubMedCentralCrossRef
20.
go back to reference Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–60.PubMedCrossRef Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–60.PubMedCrossRef
21.
go back to reference Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960;2:1662. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960;2:1662.
22.
go back to reference Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.PubMedCrossRef Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.PubMedCrossRef
23.
go back to reference Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.PubMedCrossRef Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.PubMedCrossRef
24.
go back to reference Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.PubMedCrossRef Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.PubMedCrossRef
26.
go back to reference Xiao D, Chen Z, Wu S, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020;8(11):1081–93.PubMedCrossRef Xiao D, Chen Z, Wu S, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020;8(11):1081–93.PubMedCrossRef
27.
go back to reference Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026-1041. PubMedCrossRef Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026-1041. PubMedCrossRef
28.
go back to reference Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respiratory Medicine. 2014;2(6):497–506.PubMedCrossRef Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respiratory Medicine. 2014;2(6):497–506.PubMedCrossRef
29.
go back to reference Cottini M, Licini A, Lombardi C, et al. Clinical Characterization and Predictors of IOS-Defined Small-Airway Dysfunction in Asthma. J Allergy Clin Immunol Pract. 2020;8(3):997–1004.e2.PubMedCrossRef Cottini M, Licini A, Lombardi C, et al. Clinical Characterization and Predictors of IOS-Defined Small-Airway Dysfunction in Asthma. J Allergy Clin Immunol Pract. 2020;8(3):997–1004.e2.PubMedCrossRef
30.
go back to reference Bickel S, Popler J, Lesnick B, et al. Impulse oscillometry: interpretation and practical applications. Chest. 2014;146(3):841–7.PubMedCrossRef Bickel S, Popler J, Lesnick B, et al. Impulse oscillometry: interpretation and practical applications. Chest. 2014;146(3):841–7.PubMedCrossRef
31.
go back to reference Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323–41.PubMedPubMedCentralCrossRef Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323–41.PubMedPubMedCentralCrossRef
32.
go back to reference Labaki WW, Martinez CH, Martinez FJ, et al. The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(11):1372–9.PubMedPubMedCentralCrossRef Labaki WW, Martinez CH, Martinez FJ, et al. The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(11):1372–9.PubMedPubMedCentralCrossRef
33.
go back to reference Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015;175(9):1539–49.PubMedPubMedCentralCrossRef Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015;175(9):1539–49.PubMedPubMedCentralCrossRef
34.
go back to reference de Jong K, Boezen HM, Kromhout H, et al. Occupational exposure to vapors, gases, dusts, and fumes is associated with small airways obstruction. Am J Respir Crit Care Med. 2014;189(4):487–90.PubMedCrossRef de Jong K, Boezen HM, Kromhout H, et al. Occupational exposure to vapors, gases, dusts, and fumes is associated with small airways obstruction. Am J Respir Crit Care Med. 2014;189(4):487–90.PubMedCrossRef
35.
go back to reference Paulin LM, Smith BM, Koch A, et al. Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. Ann Am Thorac Soc. 2018;15(12):1411–9.PubMedPubMedCentralCrossRef Paulin LM, Smith BM, Koch A, et al. Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. Ann Am Thorac Soc. 2018;15(12):1411–9.PubMedPubMedCentralCrossRef
36.
go back to reference Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment [published online ahead of print, 2022 Apr 12]. Lancet Respir Med. 2022;S2213-2600(21):00506–3. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment [published online ahead of print, 2022 Apr 12]. Lancet Respir Med. 2022;S2213-2600(21):00506–3.
37.
go back to reference Lange P, Celli B, Agustí A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373(2):111–22.PubMedCrossRef Lange P, Celli B, Agustí A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373(2):111–22.PubMedCrossRef
38.
go back to reference Marott JL, Ingebrigtsen TS, Çolak Y, Vestbo J, Lange P. Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. Am J Respir Crit Care Med. 2020;202(2):210–8.PubMedPubMedCentralCrossRef Marott JL, Ingebrigtsen TS, Çolak Y, Vestbo J, Lange P. Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. Am J Respir Crit Care Med. 2020;202(2):210–8.PubMedPubMedCentralCrossRef
39.
go back to reference Voraphani N, Stern DA, Zhai J, et al. The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study. Lancet Respir Med. 2022;10(1):59–71.PubMedCrossRef Voraphani N, Stern DA, Zhai J, et al. The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study. Lancet Respir Med. 2022;10(1):59–71.PubMedCrossRef
40.
go back to reference Perret JL, Lodge CJ, Lowe AJ, et al. Childhood pneumonia, pleurisy and lung function: a cohort study from the first to sixth decade of life. Thorax. 2020;75(1):28–37.PubMedCrossRef Perret JL, Lodge CJ, Lowe AJ, et al. Childhood pneumonia, pleurisy and lung function: a cohort study from the first to sixth decade of life. Thorax. 2020;75(1):28–37.PubMedCrossRef
41.
go back to reference Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015;46(4):1104–12.PubMedPubMedCentralCrossRef Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015;46(4):1104–12.PubMedPubMedCentralCrossRef
42.
go back to reference Bhatt SP, Soler X, Wang X, et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;194(2):178–84.PubMedPubMedCentralCrossRef Bhatt SP, Soler X, Wang X, et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;194(2):178–84.PubMedPubMedCentralCrossRef
43.
go back to reference Bhatta L, Leivseth L, Carslake D, et al. Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study. Respirology. 2020;25(4):401–9.PubMedCrossRef Bhatta L, Leivseth L, Carslake D, et al. Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study. Respirology. 2020;25(4):401–9.PubMedCrossRef
44.
go back to reference Wan ES, Hokanson JE, Regan EA, et al. Significant Spirometric Transitions and Preserved Ratio Impaired Spirometry Among Ever Smokers. Chest. 2022;161(3):651–61.PubMedCrossRef Wan ES, Hokanson JE, Regan EA, et al. Significant Spirometric Transitions and Preserved Ratio Impaired Spirometry Among Ever Smokers. Chest. 2022;161(3):651–61.PubMedCrossRef
Metadata
Title
Preserved ratio impaired spirometry is associated with small airway dysfunction and reduced total lung capacity
Authors
Ningning Zhao
Fan Wu
Jieqi Peng
Youlan Zheng
Heshen Tian
Huajing Yang
Zhishan Deng
Zihui Wang
Haiqing Li
Xiang Wen
Shan Xiao
Peiyu Huang
Cuiqiong Dai
Lifei Lu
Kunning Zhou
Shengtang Chen
Yumin Zhou
Pixin Ran
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02216-1

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine